Reviewing ACI Global (OTCMKTS:ACGJ) and Viridian Therapeutics (NASDAQ:VRDN)

Viridian Therapeutics (NASDAQ:VRDN) and ACI Global (OTCMKTS:ACGJ) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, earnings, risk and dividends.

Analyst Recommendations

This is a summary of current ratings and target prices for Viridian Therapeutics and ACI Global, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	0	3	9	0	2.75
ACI Global	0	0	0	0	0.00

Viridian Therapeutics presently has a consensus target price of $35.70, suggesting a potential upside of 197.75%. Given Viridian Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Viridian Therapeutics is more favorable than ACI Global.

Volatility and Risk

Viridian Therapeutics has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, ACI Global has a beta of 2.12, suggesting that its share price is 112% more volatile than the S&P 500.

Profitability

This table compares Viridian Therapeutics and ACI Global’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-85,127.16%	-70.12%	-41.49%
ACI Global	N/A	N/A	N/A

Earnings & Valuation

This table compares Viridian Therapeutics and ACI Global”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$302,000.00	3,235.12	-$237.73 million	($3.77)	-3.18
ACI Global	N/A	N/A	N/A	N/A	N/A

ACI Global has lower revenue, but higher earnings than Viridian Therapeutics.

About Viridian Therapeutics

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

About ACI Global

ACI Global Corporation, a development stage company, through its subsidiaries, engages in the design and development of proprietary technology for the production of synthetic rubber powder and thermoplastic elastomers under Micropowder trade name in the United States. It intends to utilize Micropowder technology in its chemical composition and for the manufacture of rubber and elastomers that are used in tire plastic industries. ACI Global was founded in 1997 and is based in Greenwich, Connecticut.